PUBLISHER CORRECTION



Correction to: Peritoneal dialysis-related peritonitis caused by *Gordonia bronchialis*: first pediatric report

Valentina Bruno 1,2 \odot · James Tjon 3 · Sandy Lin 4 · Helen Groves 2,5 · Kescha Kazmi 2,5 · Michael Zappitelli 1,2 · Elizabeth Harvey 1,2 \odot

Published online: 10 January 2022

© The Author(s), under exclusive licence to International Pediatric Nephrology Association 2021

Correction to: Pediatr Nephrol

https://doi.org/10.1007/s00467-021-05313-3

The final version of this article unfortunately contained a mistake. During typesetting process, the magnitude of the WBC reported in the abstract was erroneously rendered as WBC $2,340 \times 10$ /L (59% neutrophils) and Gram-positive bacilli. The correct magnitude, however, is WBC $2,340 \times 10^6$ /L (59% neutrophils) and Gram-positive bacilli. The publisher apologizes for this mistake. The original article has been corrected. The correct Abstract is presented below.

Abstract

Introduction

Gordonia species, aerobic, weakly acid-fast, Gram-positive bacilli, are a rare cause of peritonitis in patients undergoing peritoneal dialysis (PD). We report the first pediatric case of PD-related peritonitis caused by Gordonia bronchialis.

The original article can be found online at https://doi.org/10.1007/s00467-021-05313-3.

- □ Valentina Bruno valentina.bruno@sickkids.ca
- Division of Nephrology, The Hospital for Sick Children, 555 University Avenue, Toronto, ON M5G 1X8, Canada
- Department of Paediatrics, University of Toronto, Toronto, ON, Canada
- Department of Pharmacy, The Hospital for Sick Children, Toronto, ON, Canada
- Department of Nursing, The Hospital for Sick Children, Toronto, ON, Canada
- Division of Infectious Diseases, The Hospital for Sick Children, Toronto, ON, Canada

Case presentation

A 13-year-old girl with chronic kidney disease (CKD) stage 5D, on continuous cycling PD (CCPD) for 8 years, presented with cloudy PD effluent, with no abdominal discomfort or fever. Intra-peritoneal (IP) loading doses of vancomycin and ceftazidime were started at home after obtaining a PD effluent sample, which showed WBC $2,340 \times 10^6$ /L (59% neutrophils) and Gram-positive bacilli. On admission, she was clinically well and afebrile, with no history of methicillin-resistant Staphylococcus aureus (MRSA) infection, so vancomycin was discontinued, and IP ceftazidime and cefazolin were started, following a loading dose of intravenous cefazolin. Gordonia species grew after 5 days of incubation and later identified as Gordonia bronchialis. IP vancomycin was restarted as monotherapy, empirically for a total of 3 weeks therapy. A 2-week course of oral ciprofloxacin was added, based on susceptibility testing. PD catheter replacement was advised due to the risk of recurrence but was refused. A relapse occurred 16 days after discontinuing antibiotics, successfully treated with a 2-week course of IP ceftazidime and vancomycin. The PD catheter was removed and hemodialysis initiated. She received a further 2-week course of oral ciprofloxacin and amoxicillin-clavulanate post PD catheter removal.

Conclusions

Gordonia bronchialis is an emerging pathogen in PD peritonitis and appears to be associated with a high risk of relapse. PD catheter replacement is strongly suggested.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

